Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prophase Labs Inc (PRPH)

Prophase Labs Inc (PRPH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 572
  • Shares Outstanding, K 6,022
  • Annual Sales, $ 6,770 K
  • Annual Income, $ -53,360 K
  • EBIT $ -27 M
  • EBITDA $ -19 M
  • 60-Month Beta -0.33
  • Price/Sales 0.26
  • Price/Cash Flow N/A
  • Price/Book 0.06
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.90
  • Most Recent Earnings $-1.60 on 11/19/25
  • Next Earnings Date 05/19/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 207.96%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Expected Move (DTE 0) 0.3315 (63.75%)
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A
  • Expected Range 0.1885 to 0.8515

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0680 +38.09%
on 03/25/26
0.1800 -47.83%
on 04/16/26
+0.0068 (+7.81%)
since 03/20/26
3-Month
0.0680 +38.09%
on 03/25/26
0.3000 -68.70%
on 01/23/26
-0.0462 (-32.98%)
since 01/21/26
52-Week
0.0680 +38.09%
on 03/25/26
6.6590 -98.59%
on 10/07/25
-3.0081 (-96.97%)
since 04/21/25

Most Recent Stories

More News
ProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections Platform

$201.2 Million in Gross Claims with Expanding Settlement Activity Across Multiple Insurance Carriers Active Negotiations Support Estimated $50–$60 Million Net Recovery and Near-Term Cash Flow Potential...

PRPH : 0.0939 (-1.16%)
ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections Activity

Institutional Financing Interest Emerges for Receivables-Backed Financing Following Extensive Diligence UNIONDALE, NY, March 17, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase”...

PRPH : 0.0939 (-1.16%)
ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections Initiative

Each Initiative Has the Potential to Drive Significant Liquidity and Strengthen the Company’s Balance Sheet UNIONDALE, NY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase”...

PRPH : 0.0939 (-1.16%)
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd

UNIONDALE, NY, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”) is pleased to invite investors to a webinar on Tuesday, February 3, 2026, at 4:15...

PRPH : 0.0939 (-1.16%)
ProPhase Labs Provides Crown Medical Collections Update; 250+ Insurance Payors Engaged, Approximately 50 Matters in Advanced Settlement Posture

UNIONDALE, NY, Jan. 26, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and consumer products company, today provided...

PRPH : 0.0939 (-1.16%)
ProPhase Labs Uplists from Pink Sheets to OTC Market

UNIONDALE, NY, Jan. 22, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (“ProPhase” or the “Company”), a diversified life sciences and diagnostics company, today announced that its common stock...

PRPH : 0.0939 (-1.16%)
ProPhase Labs Provides Update on Convertible Debt Conversions, Capital Structure, and Underlying Asset Value

UNIONDALE, NY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. ( OTC: PRPH ) today provided an update to shareholders regarding recent trading activity, its capital structure, and the Company’s...

PRPH : 0.0939 (-1.16%)
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories

Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call...

PRPH : 0.0939 (-1.16%)
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on December 1

UNIONDALE, NY, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) is pleased to invite investors to a webinar on December 1, 2025, at 4:15 p.m. ET. The exclusive event, hosted by...

PRPH : 0.0939 (-1.16%)
ProPhase Labs Reported Results for the Third Quarter Ended September 30, 2025, and Will Hold a Virtual Conference Call Today at 2pm ET.

ProPhase Labs in discussions for strategic initiative to realize significant underlying value in the Company. Voting for Current Proxy Critically Important. Crown Medical Achieves Final Hurdle. Appointed...

PRPH : 0.0939 (-1.16%)

Business Summary

ProPhase Labs, Inc., formerly known as The Quigley Corporation, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. The Company's mission is to develop and market natural health care pharmaceuticals and nutriceuticals...

See More

Key Turning Points

3rd Resistance Point 0.1529
2nd Resistance Point 0.1313
1st Resistance Point 0.1132
Last Price 0.0939
1st Support Level 0.0735
2nd Support Level 0.0519
3rd Support Level 0.0338

See More

52-Week High 6.6590
Fibonacci 61.8% 4.1412
Fibonacci 50% 3.3635
Fibonacci 38.2% 2.5858
Last Price 0.0939
52-Week Low 0.0680

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.